92 related articles for article (PubMed ID: 22843936)
1. Effects of intermittent 5-fluorouracil and low-dose cisplatin therapy on advanced and recurrent gastric cancer.
Kanetaka K; Enjoji A; Furui J; Nagata Y; Fujioka H; Shiogama T; Miyata A; Kishikawa H; Matsuo S; Iwata T; Kanematsu T; Eguchi S;
Anticancer Res; 2012 Aug; 32(8):3495-9. PubMed ID: 22843936
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of low dose administration of 5-fluorouracil and cisplatin in patients with advanced and recurrent gastric cancer.
Kim R; Murakami S; Ohi Y; Inoue H; Yoshida K; Toge T
Int J Oncol; 1999 Nov; 15(5):921-6. PubMed ID: 10536174
[TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy of 5-fluorouracil and low-dose cisplatin in advanced and recurrent gastric cancer: a multicenter retrospective study in Nagasaki, Japan.
Enjoji A;
Anticancer Res; 2002; 22(2B):1135-9. PubMed ID: 12168913
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of the paclitaxel, cisplatin, 5-fluorouracil and leucovorin (TPFL) regimen in the treatment of advanced or metastatic gastric cancer.
Jung JY; Kwon JH; Kim JH; Song HH; Kim I; Lee KS; Kim HJ; Zang DY; Ahn JS; Lee JA; Park YI
Oncol Rep; 2009 Feb; 21(2):523-9. PubMed ID: 19148531
[TBL] [Abstract][Full Text] [Related]
5. Continuous infusion of 5-fluorouracil and low dose cisplatin infusion for the treatment of advanced and recurrent gastric adenocarcinoma.
Chung YS; Yamashita Y; Inoue T; Matsuoka T; Nakata B; Onoda N; Maeda K; Sawada T; Kato Y; Shirasaka T; Sowa M
Cancer; 1997 Jul; 80(1):1-7. PubMed ID: 9210702
[TBL] [Abstract][Full Text] [Related]
6. Phase I dose-escalating study of 24-h continuous infusion of 5-fluorouracil in combination with weekly docetaxel and cisplatin in patients with advanced gastric cancer.
Wang B; Zhang W; Hong X; Guo Y; Li J
Cancer Chemother Pharmacol; 2009 Jan; 63(2):213-8. PubMed ID: 18343924
[TBL] [Abstract][Full Text] [Related]
7. A study of weekly paclitaxel plus 5-fluorouracil and cisplatin for patients with advanced or recurrent inoperable gastric cancer.
Gu Y; Shu Y; Xu Q
Biomed Pharmacother; 2009 May; 63(4):293-6. PubMed ID: 18848761
[TBL] [Abstract][Full Text] [Related]
8. Sequence-dependence of cisplatin and 5-fluorouracil in advanced and recurrent gastric cancer.
Koizumi W; Kurihara M; Hasegawa K; Chonan A; Kubo Y; Maekawa R; Iwasaki R; Sasai T; Fukuyama Y; Ishikawa K; Miyoshi K; Yasutake K; Hayakawa M
Oncol Rep; 2004 Sep; 12(3):557-61. PubMed ID: 15289837
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel, 5-fluorouracil, and cisplatin combination chemotherapy for the treatment of advanced gastric carcinoma.
Kim YH; Shin SW; Kim BS; Kim JH; Kim JG; Mok YJ; Kim CS; Rhyu HS; Hyun JH; Kim JS
Cancer; 1999 Jan; 85(2):295-301. PubMed ID: 10023695
[TBL] [Abstract][Full Text] [Related]
10. A combination immunochemotherapy of 5-fluorouracil, cisplatin, leucovorin, and OK-432 for advanced and recurrent gastric carcinoma.
Yoshikawa T; Tsuburaya A; Kobayashi O; Sairenji M; Motohashi H; Noguchi Y
Hepatogastroenterology; 2003; 50(54):2259-63. PubMed ID: 14696512
[TBL] [Abstract][Full Text] [Related]
11. Combination chemotherapy of continuous 5-FU infusion and low-dose cisplatin infusion for the treatment of advanced and recurrent gastric and colorectal adenocarcinomas.
Tsuji A; Morita S; Horimi T; Takasaki M; Takahashi I; Shirasaka T
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():528-34. PubMed ID: 10895205
[TBL] [Abstract][Full Text] [Related]
12. [Chemotherapy with low-dose CDDP and continuous 5-FU for the treatment of advanced gastric cancers].
Tsuji A; Morita S; Horimi T; Takasaki M; Takahashi I; Shirasaka T
Gan To Kagaku Ryoho; 1999 Jun; 26(7):933-8. PubMed ID: 10396320
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy of S-1 and low-dose twice-weekly cisplatin for advanced and recurrent gastric cancer in an outpatient setting: a retrospective study.
Tsuji A; Shima Y; Morita S; Uchida M; Okamoto K; Morita M; Horimi T; Shirasaka T
Anticancer Res; 2008; 28(2B):1433-8. PubMed ID: 18505092
[TBL] [Abstract][Full Text] [Related]
14. A combination chemotherapy of 5-fluorouracil and cisplatin against advanced gastric cancer.
Imada T; Sairenji M; Suda T; Yamamoto Y; Amano T; Motohashi H
Hepatogastroenterology; 1999; 46(25):594-600. PubMed ID: 10228867
[TBL] [Abstract][Full Text] [Related]
15. Combination chemotherapy comprising 5-fluorouracil, leucovorin, etoposide, and cis-diamminedichloroplatinum for the treatment of advanced gastric cancer.
Mochizuki F; Fujii M; Kasakura Y; Yamagata M; Kochi M; Wakabayashi K; Kanamori N; Takayama T
J Cancer Res Clin Oncol; 2002 Sep; 128(9):493-6. PubMed ID: 12242513
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer.
Wang F; Wang Z; Zhou N; An X; Xu R; He Y; Li Y
Am J Clin Oncol; 2011 Aug; 34(4):401-5. PubMed ID: 21791984
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer.
Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY
Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of mitomycin C, cisplatin and 5-fluorouracil for advanced and recurrent gastric cancer.
Kikuyama S; Inada T; Oyama R; Ogata Y
Anticancer Res; 2002; 22(6B):3633-6. PubMed ID: 12552968
[TBL] [Abstract][Full Text] [Related]
20. Intermittent FLDP: 24-h infusion of 5-FU on days 1, 3 and 5 combined with low-dose cisplatin on days 1-5 for gastric cancer, and its pharmacologic and kinetic rationale.
Terashima M; Irinoda T; Kawamura H; Takagane A; Abe K; Oyama K; Fujiwara H; Saito K; Gotoh M; Shirasaka T
Cancer Chemother Pharmacol; 2003 Mar; 51(3):240-6. PubMed ID: 12655443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
